Boehringer Ingelheim, CarthroniX ink pact to pursue small molecule therapeutics in canine oncology

"When it comes to the treatment of cancer in dogs, veterinarians have limited therapeutic options compared to other areas. Due to this unmet medical need, Boehringer Ingelheim is committed to oncology research in animal health," the company said in its recent release.

Under the agreement, Boehringer Ingelheim will test a select group of small molecules provided by CarthroniX with the goal of determining their impact on canine cancers.

Read also: Boehringer operating income edges up on Jardiance, animal health

"Cancer is the leading disease-related cause of death in dogs. Current therapies to treat cancer in dogs are often non-specific and sometimes have significant side effects. Therefore, we are searching for new potential therapeutic options to support veterinarians in their care of animals," says Dr. Marlene Hauck, Head of Oncology Research at Boehringer Ingelheim Animal Health. "The impressive work of CarthroniX in developing small molecules could potentially be an effective way to treat cancer."

Read also: Boehringer Ingelheim's empagliflozin gets CDSCO nod for heart failure with preserved ejection fraction

"We are thrilled to combine our unique molecules with the expertise and reach of the Animal Health division of Boehringer Ingelheim. We see the potential to define a new paradigm in treating canine cancers and thus have major impacts on animal health," says Hassan Serhan, PhD, CEO of CarthroniX.